Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients.
Walker UA, Bickel M, Lütke Volksbeck SI, Ketelsen UP, Schöfer H, Setzer B, Venhoff N, Rickerts V, Staszewski S. Walker UA, et al. Among authors: bickel m. J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):117-21. doi: 10.1097/00042560-200202010-00002. J Acquir Immune Defic Syndr. 2002. PMID: 11832679
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, Sabin CA, Doerr HW, Johnson MA, Loveday C, Miller V; Royal Free Centre for HIV Medicine; Goethe Universität Clinic Cohort. Phillips AN, et al. Among authors: bickel m. J Infect Dis. 2002 Oct 15;186(8):1086-91. doi: 10.1086/343801. Epub 2002 Sep 30. J Infect Dis. 2002. PMID: 12355358 Free article.
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
Antiretroviral Therapy Cohort Collaboration (ART-CC); Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA. Antiretroviral Therapy Cohort Collaboration (ART-CC), et al. AIDS. 2008 Nov 30;22(18):2481-92. doi: 10.1097/QAD.0b013e328318f130. AIDS. 2008. PMID: 19005271 Free PMC article.
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Kumar P, Johnson M, Molina JM, Rizzardini G, Cahn P, Bickel M, Wan H, Xu ZJ, Morais C, Sklar P, Greaves W; DRIVE-SHIFT Study Group. Kumar P, et al. Among authors: bickel m. J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):801-805. doi: 10.1097/QAI.0000000000002642. J Acquir Immune Defic Syndr. 2021. PMID: 33633036 Free PMC article. Clinical Trial.
333 results